Related Experiment Video
Updated: May 26, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance
Teresa Rolle1, Daniela Curto, Camilla Alovisi
1Department of Clinical Physiopathology, Section of Ophthalmology, Eye Clinic, University of Torino, Torino, Italy. teresa.rolle@unito.it
European Journal of Ophthalmology
|December 15, 2011
Summary
Timogel® preservative-free eye drops offer comparable intraocular pressure reduction to timolol 0.5% but with fewer side effects. Patients reported better tolerability and satisfaction with the once-daily Timogel® formulation.
Area of Science:
- Ophthalmology
- Pharmacology
Background:
- Glaucoma and ocular hypertension require effective intraocular pressure (IOP) management.
- Timolol 0.5% ophthalmic solution is a common treatment, often administered twice daily.
- Preservative-free formulations may offer improved tolerability.
Purpose of the Study:
- To compare the efficacy, safety, and tolerability of once-daily Timogel® preservative-free versus twice-daily timolol 0.5%.
- To evaluate IOP reduction, side effect profiles, and patient acceptance in glaucoma and ocular hypertension patients.
Main Methods:
- A randomized study involving 75 patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG).
- Patients were initially treated with timolol 0.5% twice daily and then switched to Timogel® once daily.
- Evaluations included IOP measurements, side effect assessment, Schirmer test, tear break-up time (BUT), and patient-reported outcomes.
Main Results:
- Both treatments achieved similar IOP reduction (23.6% vs 22.3%).
- Timogel® demonstrated significantly fewer local and systemic side effects.
- Patients experienced improved ocular surface parameters (Schirmer, BUT) and reduced dryness with Timogel®.
- Patient satisfaction was higher with Timogel® (82% vs 61%).
Conclusions:
- Once-daily Timogel® preservative-free provides 24-hour IOP control with a superior safety and tolerability profile compared to timolol 0.5% twice daily.
- The once-daily regimen enhances patient acceptance and compliance.
- Timogel® is a well-accepted alternative for managing glaucoma and ocular hypertension.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...